1. Executive Summary

2. Market Overview: United States Flu Vaccine Market (2010 -  2024)

3. United States Number of Persons Vaccinated with Flu Vaccine (2010 - 2024)
3.1 Number of Children Vaccinated
3.2 Number of Adults Vaccinated

4. Key Drivers and Inhibitors of the United States Flu Vaccine Market
4.1 Market Drivers
4.2 Market Inhibitors

5. United States Flu Vaccine Production, Price, Consumption, Supply, Distribution, Demand and Specification
5.1 Flu Vaccine Price Trends
5.1.1 Pediatric Flu Vaccine Price Trends
5.1.2 Adult Flu Vaccine Price Trends
5.2 United States Flu Vaccine Production, Supply, and Allocation (By Companies)
5.3 United States Flu Vaccine Distribution & Demand
5.4 Flu Vaccine Effectiveness
5.5 Managing Flu with Rapid Diagnostic Testing
5.6 Distribution Method of Flu Vaccination

6. United States Flu Vaccine Market – Reimbursement & Regulatory System
6.1 Reimbursement System
6.2 Regulation System

7. Market Dynamics – Mergers, Acquisitions, Key Agreements & Collaborations
7.1 Merger & Acquisitions
7.2 Collaboration Deal
7.3 Licensing, Exclusive & Distribution Agreement Deal
7.3.1 Licensing Agreement
7.3.2 Exclusive Agreement
7.3.3 Distribution Agreement

8. Flu Vaccine – Promising Vaccine in Clinical Development
8.1 Quadrivalent Seasonal Influenza VLP Vaccine
8.2 VN – 100
8.3 Seasonal Influenza VLP Vaccine
8.4 M–001

9. Flu Vaccine – Clinical Trial Insights by Phase, Company & Country
9.1 Year 2017
9.2 Year 2016

10. Key Companies Analysis
10.1 Sanofi Pasteur
10.1.1 Business Overview
10.1.2 Flu Vaccine Outlook
10.1.2.1 Fluzone High–Dose Vaccine
10.1.2.2 Fluzone Quadrivalent Vaccine
10.1.2.3 Intradermal (ID) Trivalent Flu Vaccine
10.1.2.4 Vaxigrip Vaccine
10.1.3 Flu Vaccine Sales Analysis & Forecast (2011 - 2024)
10.1.4 Flu Vaccine – Latest Development and Trends
10.2 GlaxoSmithKline (GSK)
10.2.1 Business Overview
10.2.2 Flu Vaccine Outlook
10.2.2.1 Fluarix Quadrivalent
10.2.2.2 Flulaval Quadrivalent
10.2.3 Flu Vaccine Sales Analysis & Forecast (2011 - 2024)
10.2.4 Flu Vaccine – Latest Development & Trends
10.3 Seqirus (CSL Limited)
10.3.1 Business Overview
10.3.2 Flu Vaccine Outlook
10.3.2.1 Flucelvax Quadrivalent
10.3.2.2 Afluria Quadrivalent
10.3.2.3 Agrippal
10.3.2.4 Fluad
10.3.2.5 Fluvirin
10.3.2.6 Fluvax
10.3.3 Flu Vaccine – Latest Development & Trends
List of Tables

Table 5–2: United States – Pediatric Flu Vaccine Price, 2017 – 2018
Table 5–3: United States – Adult Flu Vaccine Price, 2017 – 2018
Table 5–4: United States – Flu Vaccine Production, Supply, and Allocation
Table 5–5: Total Percentage of Flu Vaccines Released by Week,2016 – 2017
Table 5–6: Total Percentage of Flu Vaccines Released by Week,2015 – 2016
Table 5–7: Total Percentage of Flu Vaccines Released by Week,2014 – 2015
Table 5–8: Adjusted Vaccine Effectiveness Estimates for Flu Seasons, 2005 – 2016
Table 5–9: Influenza Virus Testing Methods
Table 5–10: Distribution of Flu Vaccination
Table 6–1: United States – Simplified Regulatory Pathway from Preclinical to the Marketing Authorization
Table 7–1: Flu Vaccine Market – Merger & Acquisitions (Million US$),2003 – 2017
Table 7–2: Flu Vaccine Market – Collaborations Deal,2007 – 2017
Table 7–3: Flu Vaccine Market – Licensing Agreement,2007 – 2016
Table 7–4: Flu Vaccine Market – Exclusive Agreement,2009 – 2016
Table 7–5: Flu Vaccine Market – Distribution Agreement,2005 – 2016


List of Figures

Figure 2 1: United States – Flu Vaccine Market (Million US$),2010 – 2016
Figure 2 2: United States – Forecast for Flu Vaccine Market (Million US$),2017 – 2024
Figure 3 1: United States – Total Number of Persons Vaccinated(Thousand), 2010 – 2016
Figure 3 2: United States – Forecast for Total Number of Persons Vaccinated(Thousand), 2017 – 2024
Figure 3 3: United States – Number of Children Vaccinated(Thousand),2010 – 2016
Figure 3 4: United States – Forecast for Number of Children Vaccinated(Thousand),2017 – 2024
Figure 3 5: United States – Number of Adults Vaccinated(Thousand),2010 – 2016
Figure 3 6: United States – Forecast for Number of Adults Vaccinated(Thousand),2017 – 2024
Figure 5 1: United States – Flu Vaccine Doses Distributed, By Season(Million),2010 – 2017
Figure 10 1: Sanofi Pasteur – Flu Vaccine Net Sales (Million US$),2011 – 2016
Figure 10 2: Sanofi Pasteur – Forecast for Flu Vaccine Net Sales (Million US$),2017 – 2024
Figure 10 3: GSK – Flu Vaccine Net Sales (Million US$),2011 – 2016
Figure 10 4: GSK – Forecast for Flu Vaccine Net Sales (Million US$),2017 – 2024